Tyme Technologies — FY2019 Earnings Presentation
20 slides from Tyme Technologies's earnings presentation, May 29, 2019
Slide 1: 4Q & FY 2019 Conference Call
4Q & FY 2019 Conference Call May 29, 2019 NASDAQ: TYME Exhibit 99.2
Slide 2: TYME Conference Call Participants
TYME Conference Call Participants Business Highlights and 2019 Milestones Steve Hoffman, Chairman & Chief Executive Officer Clinical Development Progress Michele Korfin, R.Ph., M.B.A., Chief Operating Officer Giuseppe Del Priore, M.D., M.P.H., Chief Medical Officer Corporate and Financial Update Ben
Slide 3: Safe Harbor Statement
YA, oa Safe Harbor Statement In addition to historical information, this presentation contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this presentation include, without lim
Slide 4: TYME Technologies
TYME Technologies TYME is an emerging biotechnology company focused on exploring novel therapeutic approaches designed to target cancer’s unique metabolism TYME is advancing proprietary cancer metabolism-based therapies (CMBTs™) for difficult-to-treat cancers
Slide 5: Business Updates and 2019 Milestones
Business Updates and 2019 Milestones Steve Hoffman, Chairman & Chief Executive Officer
Slide 6: 2019 Key Milestones Position TYME for Short- and Long-Term Value Creation
2019 Key Milestones Position TYME for Short- and Long-Term Value Creation Updated Top-Line Phase II Results of TYME-88-Panc Study May 29, 2019 Initiate Part 2 of Tyme-88-Panc Pivotal Trial Report SM-88 Preclinical Data Results Initiate PanCAN Precision Promise(SM) Pivotal Trial Initiated JAF Ewing’s
Slide 7: Clinical Development Progress
Clinical DEVELOPMENT PROGRESS Michele Korfin, R.Ph., M.B.A., Chief Operating Officer Giuseppe Del Priore, M.D., M.P.H., Chief Medical Officer
Slide 8: SM-88 First Human Study Published in Investigational New Drugs
SM-88 First Human Study Published in the Journal Investigational New Drugs Success in pancreatic cancer may offer a path for SM-88 development into many of the 15 advanced cancers where imaging responses were demonstrated Cancers with Demonstrated Responses to SM-88 Pancreatic Breast Ovarian Prostat
Slide 9: SM-88 Proof-of-Concept: First Human Study in Metastatic Cancer
Overall Survival (months) RECIST Designation1 Median OS of 29.8 Months SM-88 Proof-of-Concept: First Human Study in Metastatic Cancer Phase 1 with 30 patients who had actively progressing metastatic cancer and received only SM-88 Therapy2 29.8 month median overall survival 13 months of progression f
Slide 10: SM-88 Monotherapy Pivotal Trial in Metastatic Pancreatic Cancer
Focus on 3rd line patients Trial design will reflect FDA protocol evaluation Randomized and primary endpoint is overall survival SM-88 Monotherapy in Patients with Radiographically Progressing Metastatic Pancreatic Cancer (Phase II/III) Structure: Part 1 single-arm, Part 2 randomized Sites: ~35 acro
Slide 11: Updated Data from Ongoing Tyme-88-Panc Phase II Study
Updated Data from Ongoing Tyme-88-Panc Phase II Study Enrollment completed with 49 patients, including 39 evaluable patients Overall survival (OS) of evaluable patients trending to be approximately double the reported OS of this patient population Estimated OS for this patient population of 2.0 to 2
Slide 12: Prostate Cancer: Clinical Trial Shows Potential To Postpone Hormone Therapy
Prostate Cancer: Clinical Trial Shows Potential To Postpone Hormone Therapy Based on Encouraging ASCO GU Data EFFICACY SAFETY Circulating Tumor Cell Response Radiographic Progression Free Survival Radiographic Progression-Free Non-Metastatic Radiographic Progression Reported Adverse Event by Causali
Slide 13: Advocacy Partners
Advocacy Partners Michele Korfin, R.Ph., M.B.A., Chief Operating Officer
Slide 14: PanCAN Precision Promise Clinical Trial Consortium Sites
PanCAN Precision PromiseSM Clinical Trial Consortium Sites PanCAN: World’s Largest Advocate Committed to Curing Pancreatic Cancer Precision Promise is the first response-adaptive randomized clinical trial platform for pancreatic cancer patients in the world and the Pancreatic Cancer Action Network’s
Slide 15: Ewing's and High-risk Sarcoma: TYME, Dr. Sant Chawla and JAF
Ewing’s accounts for 30% of bone cancers in children Tumor of the bone or soft tissue, most often in the pelvis, thigh, lower leg, upper arm and chest wall 30% 5-year survival rate for metastatic disease All sarcomas represent 12,000 new cases annually in U.S. alone JAF will fund the trial and use i
Slide 16: Positioned for Success
positioned for success Ben R. Taylor, President & Chief Financial Officer
Slide 17: Fourth Quarter and Full Year 2019 Cash Results
Fourth Quarter and Full Year 2019 Cash Results Financials: Cash Basis (in thousands) FY Q4 2019 FY 2019 Research and Development $2,181 $11,799 General and Administrative $1,979 $8,920 Total Operating Cash Usage* $4,160 $20,719 Balance Sheet FY 2019 Cash Balance on March 31, 2019 $14,302 April 2 Fin
Slide 18: Expanding Innovative Pipeline of Cancer Metabolism-Based Compounds
Expanding Innovative Pipeline of Cancer Metabolism-Based Compounds (CMBTs) *Investigator-initiated trial GA = gemcitabine/Abraxane® * TYME-88-Panc Pivotal Part 2: Initiate in 2019 PP: Initiate in 2019 PP: Initiate following 2nd Line Enrollment Completed Initiated in 2Q2019 To be disclosed
Slide 19: 2019 Creates Pivotal Inflection Point with Multiple Value Drivers
Milestone Timing Clinical Data Initial data analysis of Phase II Tyme-88-Panc metastatic pancreatic cancer at ASCO GI 1Q19 Update of Phase II prostate study at ASCO GU 1Q19 Peer-reviewed publication of SM-88 First Human Study 1H19 Final Phase II prostate study data 2H19 Updated presentation of Tyme-
Slide 20: TYME contact information
TYMEO 17 State Street 7™ FLOOR NEW YORK, NY 10004 NASDAQ: TYME INFO@TYMEINC.COM TYMEINC.COM